公开(公告)号：US20240360080A1

公开(公告)日：2024-10-31

申请号：US18520037

申请日：2023-11-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi HATTORI ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Norihito TOKUNAGA ,  Alexander Martin PAWLICZEK ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO

IPC: C07D207/14 ,  C07D403/06 ,  C07D407/08 ,  C07D417/06

CPC classification number: C07D207/14 ,  C07D403/06 ,  C07D407/08 ,  C07D417/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230037557A1

公开(公告)日：2023-02-09

申请号：US17780125

申请日：2020-11-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yoshiteru ITO ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Tatsuki KOIKE ,  Norihito TOKUNAGA ,  Eiji KIMURA ,  Alexander Martin PAWLICZEK ,  Marilena PIRA ,  Javier MIGUELEZ-RAMOS

IPC: C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230040770A1

公开(公告)日：2023-02-09

申请号：US17427490

申请日：2020-01-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi HATTORI ,  Yuhei MIYANOHANA ,  Tatsuki KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Norihito TOKUNAGA ,  Alexander Martin PAWLICZEK ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO

IPC: C07D403/06 ,  C07D207/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20210276949A1

公开(公告)日：2021-09-09

申请号：US17239191

申请日：2021-04-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi HATTORI ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Norihito TOKUNAGA ,  Alexander Martin PAWLICZEK ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO

IPC: C07D207/14 ,  C07D407/08 ,  C07D417/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.